ArticleIndian journal of ophthalmology2026
Evaluation of the effect of brinzolamide 1% ophthalmic suspension on nystagmus using videonystagmography.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of topical brinzolamide (Azopt) eye drops on nystagmus using videonystagmography in infants and children.
methodsSetting: Institutional (Cairo University Hospitals). Study population: Both eyes of 40 patients, presenting with nystagmus, with a maximal age of 14 years, were included in this prospective, nonrandomized, unmasked study. Intervention: Clinical evaluation and videonystagmography were carried out on entry, at 1 month, and 6 months of Azopt instillation and 1 month after its discontinuation. Azopt was stopped at 1 month in case of deterioration. Main outcome measures: The primary outcome of the study was the change in nystagmus intensity at 4 weeks of Azopt treatment, based on videonystagmography.
resultsMean age was 5.7 ± 3.3 years. There was a significant decrease in mean nystagmus amplitude from 8.39 ± 7.67, on entry, to 5.95 ± 5.31, 5.27 ± 4.64, and 4.18 ± 3.65 degrees at 1 month, 6 months, and 1 month after discontinuation ( P < 0.05). There was a significant decrease in slow phase velocity (SPV) from 29.53 ± 22.19, on entry, to 20.43 ± 18.62 degrees/second at 6 months, and in nystagmus intensity from 1018.4 ± 1530.9, on entry, to 319.3 ± 322.05 at 6 months ( P < 0.05). Decrease in nystagmus frequency and visual improvement were insignificant ( P > 0.05). At 1 month, nystagmus intensity decreased in 62.5%, but increased in 32.5%. No side effects were documented.
conclusionAzopt eye drops significantly reduced nystagmus in infants and children, without side effects. Worsening of nystagmus was, however, noted in around one-third of the cases, so close follow-up is essential for timely discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.